ArticleJournal of market access & health policy2023
The association between body mass index groups and metabolic comorbidities with healthcare and medication costs: a nationwide biobank and registry study in Finland.
Article in Journal of market access & health policy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Indirect costs constitute a major part of the total economic burden of obesity: a Finnish population-based cohort study.BMC public health · 2025Article
- Prevalence of obesity-related multimorbidity and its health care costs among adults in the United States.Journal of managed care & specialty pharmacy · 2025Article
- Longitudinal economic burden of incident complications among metabolic syndrome populations.Cardiovascular diabetology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe increasing prevalence of obesity imposes a significant cost burden on individuals and societies worldwide.
objectiveIn this nationally representative study, the association between body mass index (BMI) groups and the number of metabolic comorbidities (MetC) with total direct costs was investigated in the Finnish population. STUDY DESIGN, SETTING, AND
participantsThe study cohort included 5,587 adults with BMI ≥18.5 kg/m
main outcome measureThe primary outcome was total direct costs (costs of primary and secondary HCRU and prescription medications).
resultsClass I (BMI 30.0-34.9 kg/m
conclusionTo manage the cost burden of obesity, treatment should be given equal consideration as other chronic diseases, and BMIs ≥30.0 kg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.